Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May 27;12(1):293.
doi: 10.1186/s13104-019-4337-6.

Evaluating the influence of common antibiotics on the efficacy of a recombinant immunotoxin in tissue culture

Affiliations

Evaluating the influence of common antibiotics on the efficacy of a recombinant immunotoxin in tissue culture

Yuyi Zhu et al. BMC Res Notes. .

Abstract

Objective: Recombinant immunotoxins (RITs) are antibody-toxin fusion proteins that can selectively eliminate populations of cells expressing specific surface receptors. They are in evaluation as therapeutic agents for cancer. RITs based on Pseudomonas exotoxin A (PE) are in use clinically for the treatment of hairy cell leukemia, and under trial for the treatment of other cancers. In an effort to improve the efficacy of PE-based RITs, we evaluated the potential of combination therapy with several common antibiotics (tetracycline, chloramphenicol, streptomycin, linezolid, fusidic acid, and kanamycin) on human cell lines HEK293, OVCAR8, and CA46. Antibiotics were selected based on their potential to inhibit mitochondrial protein synthesis and disrupt energy metabolism in cancer cells.

Results: Tetracycline, chloramphenicol, linezolid, and fusidic acid alone killed cultured human cells at high concentrations. At high but nontoxic concentrations of each antibiotic, only chloramphenicol treatment of the Burkitt's lymphoma cell line CA46 showed enhanced cytotoxicity when paired with an anti-transferrin receptor/PE RIT. This result, however, could not be replicated in additional Burkitt's lymphoma cell lines Ramos and Raji. Although the six antibiotics we tested are not promising candidates for RIT combination therapy, we suggest that fusidic acid could be considered independently as a potential cancer therapeutic.

Keywords: Antibiotics; Combination therapy; Cytotoxicity; HB21-LR; Mitochondrial translation; Pseudomonas exotoxin A; Recombinant immunotoxins; Translation inhibition.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Responses of human cell lines to antibiotic combination treatment. Cytotoxicity assays were performed evaluating human cell lines HEK293, CA46, and OVCAR8 in response to the recombinant immunotoxin HB21-LR in the presence and absence of various antibiotics. EC50 values of each treatment condition are plotted. Error bars indicate standard error of the mean. All values are the average of at least three separate experiments. The P value shown is from a two-tailed, paired T test and reflects a significant difference between EC50 values of an antibiotic-treated and untreated control. Cell lines HEK293 (a), OVCAR8 (b), and CA46 (c) were evaluated in combination with antibiotics chloramphenicol, tetracycline, fusidic acid, kanamycin, linezolid, and streptomycin. Cell lines Ramos (d) and Raji (d) were evaluated in combination with chloramphenicol

Similar articles

Cited by

References

    1. Weldon JE, Pastan I. A guide to taming a toxin—recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J. 2011;278:4683–4700. doi: 10.1111/j.1742-4658.2011.08182.x. - DOI - PMC - PubMed
    1. Antignani A, Fitzgerald D. Immunotoxins: the role of the toxin. Toxins. 2013;5(8):1486–1502. doi: 10.3390/toxins5081486. - DOI - PMC - PubMed
    1. Polito L, Djemil A, Bortolotti M. Plant toxin-based immunotoxins for cancer therapy: a short overview. Biomedicines. 2016;4(2):12. doi: 10.3390/biomedicines4020012. - DOI - PMC - PubMed
    1. Spiess K, Jakobsen MH, Kledal TN, Rosenkilde MM. The future of antiviral immunotoxins. J Leukoc Biol. 2016;99(6):911–925. doi: 10.1189/jlb.2MR1015-468R. - DOI - PubMed
    1. Babavalian E, Zeinoddini M, Saeedinia AR, Mohammadi R, Xodadadi N. Design of a recombinant immunotoxin against the human granulocyte-colony stimulating factor receptor. Mol Biol Rep. 2018 doi: 10.1007/s11033-018-4567-z. - DOI - PubMed

MeSH terms